192 related articles for article (PubMed ID: 25026941)
1. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
[TBL] [Abstract][Full Text] [Related]
3. RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.
Germano A; Rapa I; Volante M; De Francia S; Migliore C; Berruti A; Papotti M; Terzolo M
Mol Cell Endocrinol; 2015 Feb; 401():105-10. PubMed ID: 25497672
[TBL] [Abstract][Full Text] [Related]
4. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.
Baudin E; Pellegriti G; Bonnay M; Penfornis A; Laplanche A; Vassal G; Schlumberger M
Cancer; 2001 Sep; 92(6):1385-92. PubMed ID: 11745214
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
[TBL] [Abstract][Full Text] [Related]
6. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.
Faggiano A; Leboulleux S; Young J; Schlumberger M; Baudin E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):110-3. PubMed ID: 16402938
[TBL] [Abstract][Full Text] [Related]
7. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells.
Hescot S; Slama A; Lombès A; Paci A; Remy H; Leboulleux S; Chadarevian R; Trabado S; Amazit L; Young J; Baudin E; Lombès M
Endocr Relat Cancer; 2013 Jun; 20(3):371-81. PubMed ID: 23696597
[TBL] [Abstract][Full Text] [Related]
8. [Practical use of o,p'DDD in adrenocortical carcinoma].
Bacchetta J; Droz JP
Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
[TBL] [Abstract][Full Text] [Related]
9. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
[TBL] [Abstract][Full Text] [Related]
10. The effects of mitotane and 1α,25-dihydroxyvitamin D
Rubin B; Pilon C; Pezzani R; Rebellato A; Fallo F
J Endocrinol Invest; 2020 Mar; 43(3):357-367. PubMed ID: 31587178
[TBL] [Abstract][Full Text] [Related]
11. The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.
Lehmann TP; Wrzesiński T; Jagodziński PP
Mol Med Rep; 2013 Mar; 7(3):893-900. PubMed ID: 23254310
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
[TBL] [Abstract][Full Text] [Related]
13. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
14. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
Stigliano A; Cerquetti L; Borro M; Gentile G; Bucci B; Misiti S; Piergrossi P; Brunetti E; Simmaco M; Toscano V
Endocr Relat Cancer; 2008 Mar; 15(1):1-10. PubMed ID: 18310271
[TBL] [Abstract][Full Text] [Related]
15. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.
Maher VM; Trainer PJ; Scoppola A; Anderson JV; Thompson GR; Besser GM
Q J Med; 1992 Sep; 84(305):671-9. PubMed ID: 1480741
[TBL] [Abstract][Full Text] [Related]
16. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
[TBL] [Abstract][Full Text] [Related]
17. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
[TBL] [Abstract][Full Text] [Related]
18. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
Cerquetti L; Sampaoli C; Amendola D; Bucci B; Misiti S; Raza G; De Paula U; Marchese R; Brunetti E; Toscano V; Stigliano A
Int J Oncol; 2010 Aug; 37(2):493-501. PubMed ID: 20596677
[TBL] [Abstract][Full Text] [Related]
19. Effect of o,p'DDD therapy on endogenous ACTH concentrations in dogs with hypophysis-dependent hyperadrenocorticism.
Nelson RW; Feldman EC; Shinsako J
Am J Vet Res; 1985 Jul; 46(7):1534-7. PubMed ID: 2992329
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.
Schteingart DE; Sinsheimer JE; Counsell RE; Abrams GD; McClellan N; Djanegara T; Hines J; Ruangwises N; Benitez R; Wotring LL
Cancer Chemother Pharmacol; 1993; 31(6):459-66. PubMed ID: 8453685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
